Page 1,806«..1020..1,8051,8061,8071,808..1,8201,830..»

Health Beat: Stem cells reverse multiple sclerosis

Posted: April 9, 2015 at 7:48 am

SALT LAKE CITY, Utah -

Rachel Taylor was diagnosed with multiple sclerosis 14 years ago.

"It was terrifying. It was like having a wet, heavy blanket put over your life. I was active. I was a runner. I was outdoors playing, and over the course of a few months, I couldn't figure out why I couldn't keep up" Taylor recalled.

Taylor knew what was wrong. She'd been working with the MS Society bike rides for years.

Taylor is in remission now, but she is still thrilled with Tom Lane, professor of pathology at the University of Utahs stem cell discovery.

"We have animals that are paralyzed that cannot right themselves, and once we engraft the neural stem cells into the spinal cords, within three weeks, the majority of the animals, about 80 to 85 percent, will regain motor skills," Lane said.

Researchers said MS damages myelin, a layer around nerve cells. Once injected, the human neural cells stimulate the mouse's own cells to repair the damage. When nerve cell function returns, the mice can walk and run again.

Taylor said the discovery could be life-changing for many of her friends. Researchers said after the mice regained function, their bodies rejected the stem cells, which vanished, eliminating the possibility that those cells could become tumors.

Lane is hoping this procedure could be ready for human clinical trials in two to three years.

DOWNLOAD and VIEW research summary and an in-depth interview with the doctor

Read the original post:
Health Beat: Stem cells reverse multiple sclerosis

Posted in Stem Cells | Comments Off on Health Beat: Stem cells reverse multiple sclerosis

TiGenix: USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas

Posted: April 9, 2015 at 7:48 am

PRESS RELEASE

USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas

Leuven (BELGIUM) - 8 April, 2015 -TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent 8,999,709 relating to the use of an adipose-derived stromal cell population in the treatment of fistula. The patent, entitled "Use of adipose tissue-derived stromal stem cells in treating fistula", expires in 2030 and provides coverage for the company's lead development product, Cx601, in the key US market.

"The issuance by the USPTO of this patent is a key achievement in our strategy for the development and commercialisation of Cx601 in the American market", said Wilfried Dalemans, Chief Technical Officer of TiGenix. "It further builds our intellectual property position in the use of eASCs in the indication we are pursuing. As such, it is an essential component of the business case for making the product available to patients in the US."

The issuance of this patent further strengthens TiGenix's intellectual property portfolio of 24 patent families which now includes 15 granted patents related specifically to its eASC platform. The pending and granted patents in TiGenix's intellectual property portfolio include patent families that are directed to its eASC platform; more specifically, to eASC compositions and therapeutic applications as well as to cell therapy delivery mechanisms and other eASC technology improvements.

Cx601 is a solution of expanded adipose-derived stem cells (eASCs) for local injection currently in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn's disease. Clinical results from the on-going European Phase III trial are expected in the third quarter of 2015. Following the positive feedback received at a meeting with the Center for Biologics Evaluation and Research within the Food and Drug Administration (FDA), TiGenix is moving ahead with the development of Cx601 for the United States market. The Company has submitted to the FDA the required documentation for a Special Protocol Assessment (SPA) of its pivotal Phase III trial design for Cx601 in the treatment of complex perianal fistulas in patients with Crohn's disease in the United States. Agreement with the FDA on the SPA will ensure that the trial design is aligned with the FDA's requirements for the future approval of Cx601. The Phase III trial in the US, if successful, together with positive data from the European Phase III trial, would enable the Company to file a biologics license application (BLA) with the FDA. The Company expects to complete the process of manufacturing technology transfer to its US-based contract manufacturing organisation (CMO), Lonza, in the first half of 2016, after which the Phase III trial of Cx601 in the US can begin.

For more information:

Richard Simpson Senior Consultant, Comfi sprl T: +32 494 578 278 richard@comfi.be

About Cx601

Cx601 is a suspension of allogeneic expanded adipose-derived stem cells (eASCs) delivered locally through intra-lesional injection. Cx601 is being developed for the treatment of perianal fistulas in Crohn's disease patients. Crohn's disease is a chronic inflammatory disease of the intestine and patients can suffer from complex perianal fistulas for which there is currently no effective treatment. In 2009, the European Commission granted Cx601 orphan designation for the treatment of anal fistulas, recognising the debilitating nature of the disease and the lack of treatment options. In a Phase II clinical trial, Cx601 showed efficacy at 24 weeks in 56% of treated fistula tracts, which is more than two times higher than the current standard of care (TNF inhibitors). Efficacy was measured as the complete closure and re-epithelisation of the fistula being treated with an absence of drainage. Additionally, 69.2% of patients demonstrated a reduction in the number of initially draining tracts. The trial also confirmed the safety of the use of allogeneic stem cells for the treatment of perianal fistula. Based on these results, TiGenix sought scientific advice from the European Medicines Agency (EMA) on the future development path of Cx601. TiGenix then initiated a randomised, double-blind, placebo-controlled Phase III trial in Europe and Israel designed to comply with the requirements laid down by the EMA. 'Madrid Network', an organisation within the Autonomous Region of Madrid which helps companies to grow through high-technology innovation, issued a soft loan to help finance this Phase III study. The programme is funded by The Secretary of State for Research, Development and Innovation (Ministry of Economy and Competitiveness) within the framework of the INNTEGRA plan. This pivotal study is intended to enable filing for marketing authorisation in Europe and to serve as a key supportive study in filing for approval in other territories, including the US. The study's primary endpoint is closure of all treated external openings draining at baseline despite gentle finger compression confirmed by MRI (no collections > 2cm). The trial has a first complete analysis of results at 24 weeks, with a follow-up analysis to be performed at 52 weeks post-treatment. Recruitment of the whole sample of patients was completed in the fourth quarter of 2014. The first clinical report is expected to be available in the third quarter of 2015. With positive results, TiGenix intends to submit a request for marketing authorisation with the EMA early in 2016. TiGenix is preparing to develop Cx601 for the US market. The company has filed for a Special Protocol Assessment (SPA) by the Food and Drug Administration (FDA) to ensure that the design of a new Phase III study to be conducted in the US is aligned with the FDA's requirements for the future approval of Cx601. The company has appointed Lonza as its contract manufacturing organisation (CMO) for the clinical development of Cx601 in the US.

Excerpt from:
TiGenix: USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas

Posted in Stem Cells | Comments Off on TiGenix: USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas

Back Pain Stem Cell Therapy Doctors Tampa – Video

Posted: April 9, 2015 at 7:42 am


Back Pain Stem Cell Therapy Doctors Tampa
http://Trinity-Spine.com (727) 372-9922 Stem Cell Therapy Doctor Reviews Everyone was so nice and helpful. They calmed my nerves about having to get this done, and even had really late hours...

By: Anderson Flanders

Link:
Back Pain Stem Cell Therapy Doctors Tampa - Video

Posted in Cell Therapy | Comments Off on Back Pain Stem Cell Therapy Doctors Tampa – Video

Regeneus hits key stem cell manufacturing milestone

Posted: April 9, 2015 at 7:42 am

(MENAFN - ProactiveInvestors)

Regeneus (ASX: RGS) has achieved a key milestone with the manufacture of its off-the-shelf stem cell therapy product Progenza for its First-in-Human trial for the treatment of osteoarthritis.

The company is on track to receive ethics approval and commence recruitment for the trial in the first-half of 2015.

Adding interest the company highlighted the benefit of using adipose or fat tissue over other tissue types by demonstrating the capacity to produce millions of therapeutic doses of Progenza from a single donor.

The production of commercial quantities of stem cells from a single donor is critical to maximise dose-to-dose consistency chief executive officer John Martin said.

This scale of production will minimise clinical trial and regulatory risks while reducing the cost of the final product.

One of the key advantages for manufacturing Progenza at industrial scale is that it uses stem cells sourced from adipose or fat tissue.

Adipose tissue is readily available from donors in large quantities and has significantly higher stem cells per gram of tissue than other tissue sources such as bone marrow or cord tissue.

Also adipose derived stem cells show greater capacity for expansion than stem cells from other tissue types.

Progenza adipose derived stem cells are adult stem cells they are not genetically modified like induced pluripotent stem cells (iPSC).

Here is the original post:
Regeneus hits key stem cell manufacturing milestone

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Regeneus hits key stem cell manufacturing milestone

Daily Digest: The horse stem cell fix is in for Colorado, and 9 other stories

Posted: April 9, 2015 at 7:42 am

Brenda Simmons hugs her horse Little Brother at her ranch in Granby late last month. Simmons and Little Brother have had stem cell therapy on their legs, preventing debilitating issues for both. (Andy Cross, The Denver Post)

Colorado Parks and Wildlife officers removed about 100 prairie dogs. (Courtesy Malia Reeves)

Your daily resource for late-breaking news, upcoming events, the Denver weather forecast, Denver traffic information, and the stories that will be talked about on Wednesday, April 8, 2015. Download our iPhone, iPad and Android apps for breaking news throughout the day.

1. THE HORSE FIX IS IN

The story of how researchers are using some horse sense to innovate stem cell joint therapies. Close to home, horses are leading humans into new territory, inspiring not only patients but researchers in regenerative therapies at Colorado State University in Fort Collins and the University of Colorado Hospital in Denver.

2. NOBLE TO CUT 100 ENERGY JOBS

Noble Energy, Colorado's second largest oil producer, said Tuesday that in the face of low prices it is reorganizing its operations cutting 100 jobs in Denver and Greeley.

3. 100 SEIZED PRAIRIE DOGS IN RODENT LIMBO

State wildlife agents and police officers seized about 100 prairie dogs from a Castle Rock woman's garage Tuesday morning, weeks after they were trapped at a controversial shopping mall development site.

4. POUNCED IN PRISON

View post:
Daily Digest: The horse stem cell fix is in for Colorado, and 9 other stories

Posted in Stem Cell Therapy | Comments Off on Daily Digest: The horse stem cell fix is in for Colorado, and 9 other stories

Adult stem cell therapy offered by Zannos G. Grekos, MD of …

Posted: April 9, 2015 at 6:57 am

Regenocyte uses adult stem cell therapy to treat diseases that have not been treatable with traditional medicine or that could only be treated through surgery or drugs. Adult stem cell treatment is being used to treat high-risk, life-threatening cardiac pulmonary, neurological and vascular diseases. Regenocytes founder Dr. Zannos Grekos and his team of international medical specialists, successfully transplant adult stem cells (autologous) to treat heart disease such as cardiomyopathy, pulmonary disease like COPD and Cystic Fibrosis,neurological disease such as Parkinsons and Alzheimers, spinal cord injuries and many other health problems with adult stem cell therapy.

Start NOW and learn how adult stem cell therapy can help you.

Through the Regenocyte adult stem cell therapy process, adult stem cells, taken from the patients own bone marrow or Adipose (fat) tissue, have been successful in treating cardiovascular disease, traumatic brain injury and many other medical conditions. Patients that once had limited options are now finding viable solutions through stem cell therapies with Regenocyte.

Adult Stem Cell Therapy can work for you. Find out HERE.

Adult stem cell therapy research has been documented to effectively treat many inoperable and last stage diseases. Stem cell therapies are used by many respected and qualified physicians around the world as an alternative treatment for more invasive procedures such as pacemakers and even organ transplant.

Go here to read the rest:
Adult stem cell therapy offered by Zannos G. Grekos, MD of ...

Posted in Mississippi Stem Cells | Comments Off on Adult stem cell therapy offered by Zannos G. Grekos, MD of …

Welcome to Atlanta Stem Cell Treatment

Posted: April 9, 2015 at 6:54 am

Welcome to Atlanta Stem Cell Treatment Anti-Aging & Life Extension

Aesthetic Body Sculpture Clinic Center of Anti-Aging is now offering several treatment packages for Anti-Aging and Life Extension including Adult Stem Cell Therapy. The Goal with all treatment packages is always to offer a better Quality of Life during the Aging Process, by optimizing the body from the inside out. Adult Stem Cell Treatment, PRP (Platelet Rich Plasma) Treatment& Bio-Identical Hormone Replacement Therapy as a combination treatment package can assist in regaining youthful energy, better sleep quality, increased sexual function, not to mention it may limit aches and pains that often come with the aging process or from sustained injuries along the way. Adult Stem Cell Therapy has also been known to reduce the symptoms of Osteoarthritis. Though we cannot guarantee results or make any claims, there seems to be a direct connection in patients receiving treatment experiencing an increase invitality and a decrease in chronic pain and fatigue.

How old would you say you feel, if you didnt know how old you really are?

Dr. Monte Slater believes that by designing individualizing programs for Anti-Aging & Life Extension along with setting realistic expectations, that everyone should experience a positive change in their day to day lives. One of the big concerns among middle aged active adults is the limitations that can be experienced when it comes to sports such as tennis, squash, golf and similar activities. Dr. Slater is a double board certified physician with a passion for Anti-Aging and Longevity. Within recent years he became very interested in Adult Stem Cell Therapy and the positive effects on the aging body. Already board certified in Anti-Aging & Regenerative Medicine, it made sense to incorporate Adult Stem Cell Therapy as an aid for a better quality life while aging.As a double board certified physician (OBGYN & Anti-Aging Regenerative Medicine),Dr. Monte Slater had to work with womens health issues daily.It was the foundation for what was yet to come. The journey has now taken him and his team to Atlanta Georgia, where he is able to offer superior medical service to folks interested in living healthier longer lives.

Read the rest here:
Welcome to Atlanta Stem Cell Treatment

Posted in Georgia Stem Cells | Comments Off on Welcome to Atlanta Stem Cell Treatment

'Fountain of Youth' discovered in mammary glands

Posted: April 9, 2015 at 6:54 am

Provided by Liam Mitchel, University of Toronto

The Fountain of Youth has been discovered and its not in Florida as Ponce de Leon claimed. Instead, it was found in the mammary glands of genetically modified mice.

A research team led by Professor Rama Khokha has found that when two factors that control tissue development are removed, you can avoid the impact of aging.

Think of tissue as a building that is constantly under renovation. The contractors would be metalloproteinases, which are constantly working to demolish and reconstruct the tissue. The architects in this case, who are trying to reign in and direct the contractors, are known as tissue inhibitors of metalloproteinases or TIMPs. When the architect and the contractors dont communicate well, a building can fall down. In the case of tissue, the result can be cancer.

To understand how metalloproteinases and TIMPs interact, medical researchers breed mice that have one or more of the four different types of TIMPs removed. Khokhas team examined the different combinations and found that when TIMP1 and TIMP3 were removed, breast tissue remained youthful in aged mice. The results are presented inNature Cell Biology.

In the normal course of aging, your tissue losses its ability to develop and repair as fast as it did when you were young. Thats because stem cells, which are abundant in your youth, decline with the passing of time. The U of T team found that with the TIMP1 and TIMP3 architects missing, the pool of stem cells expanded and remained functional throughout the lifetime of these mice.

Normally you would see these pools of stem cells, which reach their peak at six months in the mice, start to decline. As a result, the mammary glands start to degenerate, which increases the risk of breast cancer occurring, explains Khokha. However, we found that in these particular mice, the stem cells remained consistently high when we measured them at every stage of life.

The team also found that despite large number of stem cells, there was no increased risk of cancer.

Its generally assumed that the presence of a large number of stem cells can lead to an increased cancer risk, says Khokha. However, we found these mice had no greater predisposition to cancer.

The next step in this research is to understand why this is happening. Khokha is also working with her colleagues at Princess Margaret to see how altered tissue remodeling might prevent cancer development or lead to a new therapeutic treatment for patients.

See the original post here:
'Fountain of Youth' discovered in mammary glands

Posted in Florida Stem Cells | Comments Off on 'Fountain of Youth' discovered in mammary glands

Stem-cell battles: Stem-cell research in the USA is facing …

Posted: April 9, 2015 at 6:54 am

Disputes over stem-cell research have been standard operating procedure since James Thompson and John Gearhart created the first human embryonic cell (hESC) lines. Their work triggered an intense and ongoing debate about the morality, legality and politics of using hESCs for biomedical research. Stem-cell policy has caused craziness all over the world. It is a never-ending, irresolvable battle about the moral status [of embryos], commented Timothy Caulfield, research director of the Health Law Institute at the University of Alberta in Edmonton, Canada. We're getting to an interesting time in history where science is playing a bigger and bigger part in our lives, and it's becoming more controversial because it's becoming more powerful. We need to make some interesting choices about how we decide what kind of scientific inquiry can go forward and what can't go forward.

Stem-cell policy has caused craziness all over the world[i]t is a never-ending, irresolvable battle about the moral status [of embryos]

The most contested battleground for stem-cell research has been the USA, since President George W. Bush banned federal funding for research that uses hESCs. His successor, Barack Obama, eventually reversed the ban, but a pending lawsuit and the November congressional elections have once again thrown the field into jeopardy.

Three days after the election, the deans of US medical schools, chiefs of US hospitals and heads of leading scientific organizations sent letters to both the House of Representatives and the Senate urging them to pass the Stem Cell Research Advancement Act when they come back into session. The implication was to pass legislation now, while the Democrats were still the majority. Republicans, boosted in the election by the emerging fiscally conservative Tea Party movement, will be the majority in the House from January, changing the political climate. The Republicans also cut into the Democratic majority in the Senate.

Policies and laws to regulate stem-cell research vary between countries. Italy, for example, does not allow the destruction of an embryo to generate stem-cell lines, but it does allow research on such cells if they are imported. Nevertheless, the Italian government deliberately excluded funding for projects using hESCs from its 2009 call for proposals for stem-cell research. In the face of legislative vacuums, this October, Science Foundation Ireland and the Health Research Board in Ireland decided to not consider grant applications for projects involving hESC lines. The UK is at the other end of the scale; it has legalized both research with and the generation of stem-cell lines, albeit under the strict regulation by the independent Human Fertility and Embryology Authority. As Caulfield commented, the UK is ironically viewed as one of the most permissive [on stem-cell policy], but is perceived as one of the most bureaucratic.

Somewhere in the middle is Germany, where scientists are allowed to use several approved cell lines, but any research that leads to the destruction of an embryo is illegal. Josephine Johnston, director of research operations at the Hastings Center in Garrison, NY, USAa bioethics centresaid: In Germany you can do research on embryonic stem-cells, but you can't take the cells out of the embryo. So, they import their cells from outside of Germany and to me, that's basically outsourcing the bit that you find difficult as a nation. It doesn't make a lot of sense ethically.

Despite the public debates and lack of federal support, Johnson noted that the USA continues to lead the world in the field. [Opposition] hasn't killed stem-cell research in the United States, but it definitely is a headache, she said. In October, physicians at the Shepherd Center, a spinal cord and brain injury rehabilitation hospital and clinical research centre in Atlanta, GA, USA, began to treat the first patient with hESCs. This is part of a clinical trial to test a stem-cell-based therapy for spinal cord injury, which was developed by the US biotechnology company Geron from surplus embryos from in vitro fertilization.

Nevertheless, the debate in the USA, where various branches of governmentexecutive, legislative and legalweigh in on the legal system, is becoming confusing. We're never going to have consensus [on the moral status of fetuses] and any time that stem-cell research becomes tied to that debate, there's going to be policy uncertainty, Caulfield said. That's what's happened again in the United States.

Johnson commented that what makes the USA different is the rules about federally funded and non-federally funded research. It isn't much discussed within the United States, but it's a really dramatic difference to an outsider, she said. She pointed out that, by contrast, in other countries the rules for stem-cell research apply across the board.

The election of Barack Obama as US President triggered the latest bout of uncertainty. The science community welcomed him with open arms; after all, he supports doubling the budget of the National Institutes of Health (NIH) over the next ten years and dismantled the policies of his predecessor that barred it from funding projects beyond the 60 extant hESC linesonly 21 of which were viable. Obama also called on Congress to provide legal backing and funding for the research.

See original here:
Stem-cell battles: Stem-cell research in the USA is facing ...

Posted in Delaware Stem Cells | Comments Off on Stem-cell battles: Stem-cell research in the USA is facing …

Copy of 0dKXZsceBerY 1 – Video

Posted: April 9, 2015 at 12:40 am


Copy of 0dKXZsceBerY 1
Utah Stem Cells offers a variety of services using Stem Cells and Platelet Rich Plasma. Our Stem Cell Joint Regeneration has proven very effective to our patients, and it #39;s the best alternative...

By: Bill Cimikoski

Follow this link:
Copy of 0dKXZsceBerY 1 - Video

Posted in Stem Cell Videos | Comments Off on Copy of 0dKXZsceBerY 1 – Video

Page 1,806«..1020..1,8051,8061,8071,808..1,8201,830..»